SCHEMBL6457833

SCHEMBL6457833

CC(C)(c1noc(-c2ccccc2Cl)n1)c1c(Cl)cc(-n2nc(C(=O)NC(=O)O)c(=O)[nH]c2=O)cc1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
TSHR P16473 2/20 0.37
THRA P10827 1/20 0.34
KMT2A Q03164 3/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 3/20 0.33
HSD17B10 Q99714 2/20 0.33
ALOX15 P16050 1/20 0.33
RECQL P46063 1/20 0.33
AKR1B1 P15121 1/20 0.33
MEN1 O00255 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
DGAT1 O75907 1/20 0.33
RIPK1 Q13546 2/20 0.33
THRB P10828 1/20 0.32
NPC1 O15118 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
ATM Q13315 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475079 0.94 THRA (0.34) ALDH1A1TSHRTHRAKMT2AHPGD
SCHEMBL7139293 0.91 THRA (0.42) ALDH1A1TSHRTHRAKMT2AHPGD
SCHEMBL5761739 0.86 THRA (0.41) TSHRTHRAKMT2AMEN1L3MBTL1
SCHEMBL5762276 0.81 THRB (0.36) THRAKMT2AHPGDKDM4EHSD17B10
SCHEMBL6454982 0.74 THRA (0.42) THRAKMT2AMEN1L3MBTL1THRB
SCHEMBL6459710 0.73 THRB (0.40) THRAKMT2AMEN1THRBPLAT
SCHEMBL6454151 0.73 THRA (0.32) ALDH1A1THRAKMT2AKDM4EMEN1
SCHEMBL6454313 0.71 THRB (0.40) ALDH1A1THRAKMT2AHPGDMEN1
SCHEMBL6455277 0.70 THRB (0.38) THRAKMT2AMEN1THRBPLAT
SCHEMBL6457755 0.69 NPC1 (0.43) ALDH1A1TSHRKMT2AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6894046-B2 IL-5 inhibiting 6-azauracil derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2005-05-17 US disclosed
EP-1114046-B1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2003-04-23 EP disclosed
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives JANSSEN CILAG S.A. (FR) 2002-01-24 US disclosed
EP-1114046-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES Janssen Pharmaceutica N.V. (BE) 2001-07-11 EP disclosed
WO-2000017195-A1 INTERLEUKIN-5 INHIBITING 6-AZAURACIL DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2000-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020010177-A1 IL-5 inhibiting 6-azauracil derivatives ALOX5, IL5, IL6ST ALDH1A1 1746/4885TSHR 626/4885THRA 1581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.